Skip to content
A Green Sign – Lifestyle
Author:
Atrium Therapeutics
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
August 13, 2026
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
August 13, 2026
Seven Sanford Heisler Sharp McKnight Attorneys Named to Benchmark Litigation’s 2026 40 & Under Guide
August 12, 2026
Sanford Heisler Sharp McKnight’s 21 Partners All Recognized in Lawdragon’s 2026 Guide
July 29, 2026
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 20, 2026
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
July 14, 2026
Former Assistant U.S. Attorney and Veteran Trial Lawyer Brings Federal Prosecutorial Experience to Sanford Heisler’s National Civil Rights, Employment and Whistleblower Practice
July 8, 2026
Sanford Heisler Sharp McKnight Files $28 Million ERISA Representative Action Against Parsons Financial Corporation
July 1, 2026
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 23, 2026
Atrium Therapeutics Reports First Quarter 2026 Financial Results
May 14, 2026
1
2
Next Page
→